Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05117489 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT05117489 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 70 participants.
The verdict
NCT05117489, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
Interventions
- DRUG Miricorilant 150 mg
- DRUG Miricorilant 100 mg
- DRUG Miricorilant 50 mg
- DRUG Miricorilant 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-11-23 |
| Est. Completion | 2024-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05117489
The ClinicalTrials.gov registry entry for NCT05117489 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Miricorilant 150 mg is the first listed.
NCT05117489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05117489 about?
NCT05117489 is a clinical study titled "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)". This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
What is the current status of trial NCT05117489?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2021-11-23. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT05117489?
The interventions under investigation include: Miricorilant 150 mg (DRUG), Miricorilant 100 mg (DRUG), Miricorilant 50 mg (DRUG), Miricorilant 10 mg (DRUG).
Who is sponsoring clinical trial NCT05117489?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.